Numerous studies have found that RASSF1 is a potential biomarker for the diagnosis of lung, cervical, and prostate cancer, implying that our assay and primers could be effective in screening for other diseases [42,43,44]. This evidence concerns the gene RASSF1 and prostate carcinoma.